Skip to content

Rethinking the Effects of Working Memory Training on Executive Functions in Schizophrenia: A Machine Learning Approach

Rethinking the Effects of Working Memory Training on Executive Functions in Schizophrenia: A Machine Learning Approach

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109018
Enrollment
Unknown
Registered
2025-09-10
Start date
2024-05-05
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Adaptive N-back Working Memory Training Group:Adaptive N-back Working Memory Training
Non-adaptive 1-back Control Group:Non-adaptive 1-back Training
Treatment-as-Usual Group:Treatment as Usual

Sponsors

Northwest Normal University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age between 18 and 65 years; (2) Diagnosis of schizophrenia established by two resident psychiatrists according to the International Classification of Diseases, 10th Revision (ICD-10) criteria (F20.9), and further confirmed with the Structured Clinical Interview for DSM (SCID); (3) Clinically stable, defined as receiving the same type of antipsychotic medication at a maintenance dose for at least six consecutive weeks, with less than a 20% change in total Positive and Negative Syndrome Scale (PANSS) score; (4) Sufficient cognitive and communicative ability to complete experimental tasks and voluntarily provide written informed consent.

Exclusion criteria

Exclusion criteria: (1) Presence of severe physical illnesses, such as major cardiovascular or cerebrovascular diseases, epilepsy, or malignant tumors; (2) Corrected visual acuity below 0.8; (3) Long-term use of medications known to impair cognitive function (e.g., benzodiazepines, antihistamines, anticholinergics, sedatives) or a history of alcohol abuse; (4) Antipsychotic medication dosage exceeding the olanzapine-equivalent of 35 mg/day; (5) Prominent extrapyramidal symptoms or other severe adverse drug reactions that may interfere with the performance of behavioral tasks; (6) History of organic brain injury, such as traumatic brain injury or cerebrovascular disease; (7) Substance abuse within six months prior to enrollment; (8) Participation in other clinical studies within three months prior to enrollment.

Design outcomes

Primary

MeasureTime frame
Executive Function Composite Assessment;PANSS Clinical Scale;

Countries

China

Contacts

Public ContactXin Zhao

Northwest Normal University

psyzhaoxin@nwnu.edu.cn+86 139 1942 5826

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026